Research Progress of Mechanisms on Intracranial Metastasis of Non-small Cell Lung Cancer after Clinical Beneift from EGFR-TKI
10.3779/j.issn.1009-3419.2015.08.09
- VernacularTitle:非小细胞肺癌EGFR-TKI治疗临床获益后颅内转移机制研究进展
- Author:
JIANG JUAN
1
;
HU CHENGPING
Author Information
1. 中南大学湘雅医院呼吸科
- Keywords:
EGFR-TKI;
Lung neoplasms;
Intracranial metastasis
- From:
Chinese Journal of Lung Cancer
2015;(8):518-522
- CountryChina
- Language:Chinese
-
Abstract:
Currently epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is widely used for treatment of non-small cell lung cancer (NSCLC) patients withEGFR mutation. However, intracranial metastasis and progres-sion could happen to some patients while their primary tumors in lung stabilize or even shrink atfer EGFR-TKI treatment. And mechanisms on this phenomenon remain unclear. Recently, increasing studies have demonstrated that it is associated with the pharmacokinetics of EGFR-TKI, heterogeneity between primary tumors and metastases,EGFR mutation status and prolonged survival. hTerefore, we write this review to discuss the mechanisms on intracranial metastasis of NSCLC atfer clinical beneift from EGFR-TKI.
